Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.01M Buy
64,550
+3,453
+6% +$306K ﹤0.01% 1479
2025
Q4
$4.91M Sell
61,097
-5,001
-8% -$419K ﹤0.01% 1475
2025
Q3
$6.45M Sell
66,098
-45,292
-41% -$3.65M ﹤0.01% 1245
2025
Q2
$7.76M Buy
111,390
+32,634
+41% +$1.86M ﹤0.01% 1482
2025
Q1
$3.91M Buy
78,756
+836
+1% +$52.9K ﹤0.01% 1688
2024
Q4
$5.44M Buy
77,920
+2,621
+3% +$218K ﹤0.01% 1564
2024
Q3
$7.9M Sell
75,299
-47,198
-39% -$5.52M ﹤0.01% 1336
2024
Q2
$17.4M Buy
122,497
+85,594
+232% +$9.87M 0.01% 913
2024
Q1
$4.12M Sell
36,903
-2,167
-6% -$258K ﹤0.01% 1343
2023
Q4
$5.07M Buy
39,070
+1,862
+5% +$257K ﹤0.01% 1235
2023
Q3
$6.07M Sell
37,208
-6,143
-14% -$1.08M ﹤0.01% 1138
2023
Q2
$5.78M Hold
43,351
﹤0.01% 1170
2023
Q1
$5.78M Buy
+43,351
New +$5.09M ﹤0.01% 1170
2022
Q4
Sell
-40,310
Closed -$2.44M 2527
2022
Q3
$2.44M Sell
40,310
-1,570
-4% -$101K ﹤0.01% 1499
2022
Q2
$2.3M Hold
41,880
﹤0.01% 1562
2022
Q1
$3.16M Buy
41,880
+5,158
+14% +$352K ﹤0.01% 1553
2021
Q4
$2.74M Sell
36,722
-1,446
-4% -$85.7K ﹤0.01% 1722
2021
Q3
$1.8M Buy
38,168
+7,230
+23% +$315K ﹤0.01% 1886
2021
Q2
$1.25M Buy
30,938
+5,615
+22% +$233K ﹤0.01% 2087
2021
Q1
$1.04M Hold
25,323
﹤0.01% 2069
2020
Q4
$737K Sell
25,323
-3,346
-12% -$86.6K ﹤0.01% 2132
2020
Q3
$631K Buy
28,669
+3,798
+15% +$96.8K ﹤0.01% 2030
2020
Q2
$693K Sell
24,871
-8,787
-26% -$214K ﹤0.01% 1966
2020
Q1
$616K Sell
33,658
-3,532
-9% -$82.1K ﹤0.01% 1896
2019
Q4
$896K Buy
37,190
+2,936
+9% +$61.9K ﹤0.01% 1969
2019
Q3
$585K Buy
34,254
+5,151
+18% +$82.3K ﹤0.01% 2207
2019
Q2
$438K Buy
29,103
+15,136
+108% +$270K ﹤0.01% 2272
2019
Q1
$281K Buy
13,967
+67
+0.5% +$1.36K ﹤0.01% 2341
2018
Q4
$247K Hold
13,900
﹤0.01% 2298
2018
Q3
$273K Hold
13,900
﹤0.01% 2306
2018
Q2
$275K Buy
+13,900
New +$306K ﹤0.01% 2345

Other funds holding ACLS

UBS AM's ACLS Position: Q1 2026 in Review

UBS AM increased its Axcelis (ACLS) stake by 5.7% in Q1 2026, buying an estimated $306K and bringing the position to 64,550 shares worth $6.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1479.

UBS AM first reported a position in ACLS in Q2 2018 and has held it in 31 quarters since. The position peaked at $17.4M in Q2 2024. 377 funds tracked by Wall St. Rank hold ACLS as of Q1 2026.

  • UBS AM held 64,550 shares of Axcelis worth $6.01M as of Q1 2026.
  • UBS AM bought 3,453 Axcelis shares in Q1 2026, an estimated $306K.
  • Axcelis made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #1479 holding.
  • UBS AM first reported a position in Axcelis in Q2 2018 and has held it in 31 quarters since.
  • UBS AM's Axcelis position peaked at $17.4M in Q2 2024.
  • 377 funds tracked by Wall St. Rank held Axcelis as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.